4//SEC Filing
Korenberg Matthew E 4
Accession 0002001011-24-000087
CIK 0000886163other
Filed
Sep 23, 8:00 PM ET
Accepted
Sep 24, 7:41 PM ET
Size
21.4 KB
Accession
0002001011-24-000087
Insider Transaction Report
Form 4
Korenberg Matthew E
VP, Finance and CFO
Transactions
- Sale
Common Stock
2024-09-23$101.61/sh−7,090$720,379→ 50,978 total - Sale
Common Stock
2024-09-23$102.05/sh−201$20,513→ 50,777 total - Exercise/Conversion
Common Stock
2024-09-23$49.99/sh+395$19,746→ 51,172 total - Exercise/Conversion
Employee Stock Option (right to buy)
2024-09-23−395→ 0 totalExercise: $49.99Exp: 2026-02-11→ Common Stock (395 underlying) - Exercise/Conversion
Common Stock
2024-09-20$49.99/sh+4,982$249,050→ 57,052 total - Sale
Common Stock
2024-09-20$104.10/sh−6,275$653,238→ 50,777 total - Sale
Common Stock
2024-09-23$100.05/sh−2,481$248,228→ 58,068 total - Exercise/Conversion
Common Stock
2024-09-23$52.84/sh+9,377$495,481→ 60,549 total - Exercise/Conversion
Employee Stock Option (right to buy)
2024-09-20−4,982→ 395 totalExercise: $49.99Exp: 2026-02-11→ Common Stock (4,982 underlying) - Exercise/Conversion
Employee Stock Option (right to buy)
2024-09-23−9,377→ 42,436 totalExercise: $52.84Exp: 2032-05-05→ Common Stock (9,377 underlying)
Footnotes (6)
- [F1]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $104.0000 to $104.4300. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F2]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $100.0000 to $100.2750. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $101.0450 to $102.0400. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F4]The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $102.0450 to $102.0950. The Reporting Person undertakes to provide the Registrant, any securityholder of the Registrant, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F5]This Option was previously reported as a Grant of 18,464 shares on February 11, 2016, which vested in full on February 11, 2020, at an exercise price of $85.79 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer.
- [F6]This Option was previously reported as a Grant of 30,189 shares on May 5, 2022, at an exercise price of $90.68 per share, but was adjusted pursuant to the OmniAb Inc. separation from the issuer and shall be fully vested on February 5, 2026.
Documents
Issuer
LIGAND PHARMACEUTICALS INC
CIK 0000886163
Entity typeother
Related Parties
1- filerCIK 0001649903
Filing Metadata
- Form type
- 4
- Filed
- Sep 23, 8:00 PM ET
- Accepted
- Sep 24, 7:41 PM ET
- Size
- 21.4 KB